185 related articles for article (PubMed ID: 10490828)
21. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
Felix NJ; de Serres S; Meyer AA; Ting JP
J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017
[TBL] [Abstract][Full Text] [Related]
22. Class II transactivator-independent endothelial cell MHC class II gene activation induced by lymphocyte adhesion.
Collinge M; Pardi R; Bender JR
J Immunol; 1998 Aug; 161(4):1589-93. PubMed ID: 9712019
[TBL] [Abstract][Full Text] [Related]
23. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
24. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
25. Prolonged MHC class II expression and CIITA transcription in human keratinocytes.
Takagi A; Nishiyama C; Kanada S; Niwa Y; Fukuyama K; Ikeda S; Okumura K; Ogawa H
Biochem Biophys Res Commun; 2006 Aug; 347(2):388-93. PubMed ID: 16836979
[TBL] [Abstract][Full Text] [Related]
26. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
27. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
[TBL] [Abstract][Full Text] [Related]
28. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
Takamura Y; Ikeda H; Kanaseki T; Toyota M; Tokino T; Imai K; Houkin K; Sato N
Glia; 2004 Mar; 45(4):392-405. PubMed ID: 14966870
[TBL] [Abstract][Full Text] [Related]
29. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.
Goodwin BL; Xi H; Tejiram R; Eason DD; Ghosh N; Wright KL; Nagarajan U; Boss JM; Blanck G
Cell Growth Differ; 2001 Jun; 12(6):327-35. PubMed ID: 11432807
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
Radosevich M; Jager M; Ono SJ
Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
[TBL] [Abstract][Full Text] [Related]
31. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2.
Xi H; Goodwin B; Shepherd AT; Blanck G
Oncogene; 2001 Jul; 20(31):4219-27. PubMed ID: 11464288
[TBL] [Abstract][Full Text] [Related]
32. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M
Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767
[TBL] [Abstract][Full Text] [Related]
33. Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta.
Harnesk K; Swanberg M; Diez M; Olsson T; Piehl F; Lidman O
J Neuroimmunol; 2009 Jul; 212(1-2):44-52. PubMed ID: 19481818
[TBL] [Abstract][Full Text] [Related]
34. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
Bradley MB; Fernandez JM; Ungers G; Diaz-Barrientos T; Steimle V; Mach B; O'Reilly R; Lee JS
J Immunol; 1997 Aug; 159(3):1086-95. PubMed ID: 9233601
[TBL] [Abstract][Full Text] [Related]
35. MHC class II transcription in different mouse cell types. Differential requirement for protein synthesis between B cells and macrophages.
Woodward JG; Omer KW; Stuart PM
J Immunol; 1989 Jun; 142(11):4062-9. PubMed ID: 2497189
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
37. Translational control of MHC class II I-A molecules by IFN-gamma.
Goñalons E; Barrachina M; García-Sanz JA; Celada A
J Immunol; 1998 Aug; 161(4):1837-43. PubMed ID: 9712051
[TBL] [Abstract][Full Text] [Related]
38. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.
Steimle V; Siegrist CA; Mottet A; Lisowska-Grospierre B; Mach B
Science; 1994 Jul; 265(5168):106-9. PubMed ID: 8016643
[TBL] [Abstract][Full Text] [Related]
39. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes.
Lu Y; Tschickardt ME; Schmidt BJ; Blanck G
Immunol Cell Biol; 1997 Aug; 75(4):325-32. PubMed ID: 9315472
[TBL] [Abstract][Full Text] [Related]
40. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
